<DOC>
	<DOCNO>NCT02354313</DOCNO>
	<brief_summary>A phase III multicenter , randomize study Lenalidomide ( Revlimid® ) maintenance versus observation intensify induction regimen contain rituximab follow high dose chemotherapy Autologous Stem Cell Transplantation first line treatment adult patient advance Mantle Cell Lymphoma : IIL study ( MCL0208 ) .</brief_summary>
	<brief_title>STUDY WITH LENALIDOMIDE ( Revlimid® ) MAINTENANCE VS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MANTLE CELL LYMPHOMA</brief_title>
	<detailed_description>This Phase 3 , multicenter , open-label , randomize , control study determine efficacy safety lenalidomide maintenance therapy versus observation patient MCL complete partial remission first line intensify high-dose chemotherapy additioned rituximab follow ASCT . This study conduct three phase : Screening Phase , Treatment Phase Follow-up Phase</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria . 1 . Any male female adult newly diagnose mantle cell lymphoma accord WHO criterion . 2 . Biopsyproven mantle cell nonHodgkin 's lymphoma , include evidence cyclin D1 overexpression translocation ( 11 ; 14 ) ( q13 ; q32 ) FISH RTPCR . In subject whose tumor negative cyclin D1 , evidence overexpression cyclin D2 D3 immunohistochemistry acceptable . 3 . Age ≥18 year &lt; 60 ECOG performance status 03 , age 60 65 year ECOG performance status 02 , except PS impairment relate NHL . 4 . Advanced stage ( Stage III IV accord Ann Arbor stage II bulky disease define mass ≥ 5 cm B symptom ) . 5 . Measurable disease ( two diameter ) least one site . Osteoblastic bone lesion , ascites pleural effusion consider measurable disease . 6 . Written inform consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice . 7 . Be willing able comply protocol duration study . 8 . Females childbearing potential ( FCBP ) must : two negative medically supervised pregnancy test prior start study therapy . She must agree ongoing pregnancy test course study , end study therapy . This apply even patient practice complete continue sexual abstinence . Either commit continue abstinence heterosexual intercourse ( must review monthly basis ) agree use , able comply , effective contraception without interruption , 28 day prior start study drug , study therapy ( include dose interruption ) , 28 day discontinuation study therapy . The following effective method contraception Implant Levonorgestrelreleasing intrauterine system ( IUS ) Medroxyprogesterone acetate depot Tubal sterilisation Sexual intercourse vasectomise male partner ; vasectomy must confirm two negative semen analyse Ovulation inhibitory progesteroneonly pill ( i.e. , desogestrel ) 9 . Male patient must agree use condom sexual contact FCBP , even vasectomy , throughout study drug therapy , dose interruption cessation study therapy . Agree donate semen study drug therapy period end study drug therapy . 10 . All patient must understand study drug could potential teratogenic risk . They must agree abstain donate blood take study drug therapy follow discontinuation study drug therapy . They must agree share study medication another person . They must counsel pregnancy precaution risk fetal exposure . 1 . NonHodgkin 's lymphoma subtypes MCL 2 . Cytological variant small cell round nuclei mimic CLL , frequently recognize patient leukemic splenomegaly presentation without minimal involvement lymph node indolent clinical course . 3 . History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ cervix , carcinoma situ breast , incidental histological finding prostate cancer ( TNM stage T1a T1b ) within last 3 year . 4 . Major surgery , diagnostic surgery , within last 4 week . 5 . Evidence CNS involvement , patient history uncontrolled seizure , central nervous system disorder psychiatric disability consider Investigator clinically significant adversely affect compliance study drug . If clinically indicate , lumbar puncture , MRI perform screen process . 6 . Clinically significant cardiac disease ( VEF &lt; 45 % ) ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month ( New York Heart Association Class III IV heart disease ) mark impairment pulmonary function ( pulmonary diffusing capacity &lt; 50 % ) . 7 . Unacceptable hematologic value week prior start study : hemoglobin &lt; 9 g/dL , WBC &lt; 3x109/L , platelet &lt; 60x109/L , absolute neutrophil count ( ANC ) &lt; 1.5x109/L ( unless cytopenia secondary bone marrow involvement autoimmune cytopenia relate lymphoma ) . 8 . Abnormal liver function test , within one week prior study start value list : serum bilirubin &gt; 2 mg/dL , ALT AST &gt; 3 time upper normal value ; alkaline phosphatase &gt; 2.5 time upper normal value ( unless abnormality due liver involvement lymphoma ) . 9 . Abnormal renal function ( serum creatinine &gt; 2.0 mg/dL ) , unless disease relate 10 . Patients active opportunistic infection . 11 . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Patients HBcAb serology , exclude study give lamivudine prophylaxis start one week chemotherapy . HbsAg AST/ALT ifHBV DNA available , monitor every three week . If HBV DNA available , monitor along HBsAg 12 . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MANTLE CELL LYMPHOMA ( MCL )</keyword>
	<keyword>Lenalidomide ( Len )</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ASCT</keyword>
	<keyword>Revlimid</keyword>
	<keyword>High dose chemotherapy</keyword>
	<keyword>transplant</keyword>
</DOC>